NIVES study: A phase II trial of nivolumab (NIVO) plus stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC).Cristina Masini, Carmine Pinto, Annalisa Berselli et al.|Journal of Clinical Oncology|2018Cited by 5
First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES studyCristina Masini, Carmine Pinto, Patrizia Ciammella et al.|Annals of Oncology|2019Cited by 0